Documents
Application Sponsors
NDA 206510 | MERCK SHARP DOHME | |
Marketing Status
Application Products
001 | TABLET;ORAL | 150MG;EQ 300MG BASE | 0 | DUTREBIS | LAMIVUDINE; RALTEGRAVIR POTASSIUM |
FDA Submissions
TYPE 4; Type 4 - New Combination | ORIG | 1 | AP | 2015-02-06 | STANDARD |
Submissions Property Types
CDER Filings
MERCK SHARP DOHME
cder:Array
(
[0] => Array
(
[ApplNo] => 206510
[companyName] => MERCK SHARP DOHME
[docInserts] => ["",""]
[products] => [{"drugName":"DUTREBIS","activeIngredients":"LAMIVUDINE; RALTEGRAVIR POTASSIUM","strength":"150MG;EQ 300MG BASE","dosageForm":"TABLET;ORAL","marketingStatus":"Discontinued","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"02\/06\/2015","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/206510lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"02\/06\/2015","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 4 - New Combination","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/206510lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2015\\\/206510Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2015\\\/206510Orig1s000TOC.cfm\"},{\"name\":\"Summary Review (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2015\\\/206510Orig1s000SumR.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2015-02-06
)
)